Alcohol, toxins, and medications as a cause of sleep dysfunction

Handbook of Clinical Neurology

Volumn 98, Issue C, 2011, Pages 587-612

  Conroy, Deirdre A ^a   Brower, Kirk J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL DERIVATIVE; NEUROLEPTIC AGENT; PRESCRIPTION DRUG; TOXIN;

BOOK; CHEMICALLY INDUCED DISORDER; HUMAN; SLEEP DISORDER;

ALCOHOLS; ANTIPSYCHOTIC AGENTS; HUMANS; PRESCRIPTION DRUGS; SLEEP DISORDERS; TOXINS, BIOLOGICAL;

EID: 78149388457     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52006-7.00038-1     Document Type: Book

References (298)

1. Aldrich M.S., Brower K.J., Hall J.M. Sleep-disordered breathing in alcoholics. Alcohol Clin Exp Res 1999, 23:134-140.
2. Allen R., Wagman A., Funderburk F. Slow wave sleep changes: alcohol tolerance and treatment implications. Adv Exp Med Biol 1977, 85A:629-640.
3. Allen R., McCann U., Ricaurte G. Persistent effects of 3,4-methylenedioxymethamphetamine (MDMA, " ecstasy") on human sleep. Sleep 1993, 16:560-564.
4. Antonijevic I., Stalla G., Steiger A. Modulation of the sleep electroencephalogram by estrogen replacement in postmenopausal women. Am J Obstet Gynecol 2000, 182:277-282.
5. Armitage R., Cole D., Suppes T., et al. Effects of clozapine on sleep in bipolar and schizoaffective disorders. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:1065-1070.
6. Arnulf I., Konofal E., Merino-Andreu M., et al. Parkinson's disease and sleepiness. Neurology 2002, 58:1019-1024.
7. Askenasy J., Yahr M. Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy. Neurology 1985, 35:527-532.
8. Aslan S., Isik E., Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002, 25:677-679.
9. Backonja M.M. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia 1999, 40(Suppl 6):S57-S59. discussion S73-S74.
10. Balon R. Bupropion and nightmares. Am J Psychiatry 1996, 153:579-580.
11. Balon R., Yeragani V.K., Pohl R.B., et al. Lithium discontinuation: withdrawal or relapse?. Compr Psychiatry 1988, 29:330-334.
12. Bartel P., Loock M., Becker P., et al. Short-term antihypertensive medication does not exacerbate sleep-disordered breathing in newly diagnosed hypertensive patients. Am J Hypertens 1997, 10:640-645.
13. Bazil C.W. Effects of antiepileptic drugs on sleep structure: are all drugs equal?. CNS Drugs 2003, 17:719-728.
14. Bazil C.W., Battista J., Basner R.C. Gabapentin improves sleep in the presence of alcohol. J Clin Sleep Med 2005, 1:284-287.
15. Bell C., Vanderlinden H., Hiersemenzel R., et al. The effects of levetiracetam on objective and subjective sleep parameters in healthy volunteers and patients with partial epilepsy. J Sleep Res 2002, 11:255-263.
16. Bell C., Wilson S., Rich A., et al. Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers. Psychopharmacology 2003, 166:102-110.
17. Berridge C.W., Stellick R.L., Schmeichel B.E. Wake-promoting actions of medial basal forebrain beta2 receptor stimulation. Behav Neurosci 2005, 119:743-751.
18. Bertrand B., Jamart J., Marchal J., et al. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology 1996, 34:91-96.
19. Beydoun A., Uthman B.M., Sackellares J.C. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995, 18:469-481.
20. Bhatt M., Podder N., Chokroverty S. Sleep and neurodegenerative diseases. Sleep in Neurological Practice 2005, Thieme Medical Publishers, New York. K. Roos, A. Avidan (Eds.).
21. Billiard M. Lithium carbonate: effects on sleep patterns of normal and depressed subjects and its use in sleep-wake pathology. Pharmacopsychiatry 1987, 20:195-196.
22. Bonanni E., Galli R., Maestri M., et al. Daytime sleepiness in epilepsy patients receiving topiramate monotherapy. Epilepsia 2004, 45:333-337.
23. Bonnet M., Tancer M., Uhde T., et al. Effects of caffeine on heart rate and QT variability during sleep. Depress Anxiety 2005, 22:150-155.
24. Borsato G., Madrid G., Hicks R. Cigarette Smoking and Sleep Disturbance. Associated Professional Sleep Societies 2000, Sleep, Las Vegas, NV.
25. Bose-O'Reilly S., Drasch G., Beinhoff C., et al. The Mt. Diwata study on the Philippines 2000-treatment of mercury intoxicated inhabitants of a gold mining area with DMPS (2,3-dimercapto-1-propane-sulfonic acid, Dimaval). Sci Total Environ 2003, 307:71-82.
26. Bowler R.M., Mergler D., Sassine M.P., et al. Neuropsychiatric effects of manganese on mood. Neurotoxicology 1999, 20:367-378.
27. Brockhaus A., Dolgner R., Ewers U., et al. Intake and health effects of thallium among a population living in the vicinity of a cement plant emitting thallium containing dust. Int Arch Occup Environ Health 1981, 48:375-389.
28. Brower K.J. Insomnia, alcoholism and relapse. Sleep Med Rev 2003, 7:523-539.
29. Brower K., Maddahian E., Blow F., et al. A comparison of self reported symptoms and DSM-III-R criteria for cocaine withdrawal. Am J Drug Alcohol Abuse 1988, 14:347-356.
30. Brower K., Blow F., Young J., et al. Symptoms and correlates of anabolic-androgenic steroid dependence. Br J Addict 1991, 86:759-768.
31. Brower K.J., Aldrich M.S., Hall J.M. Polysomnographic and subjective sleep predictors of alcoholic relapse. Alcohol Clin Exp Res 1998, 22:1864-1871.
32. Brower K.J., Aldrich M., Robinson E.A.R., et al. Insomnia, self-medication, and relapse to alcoholism. Am J Psychiatry 2001, 158:399-404.
33. Brown L.K., Dedrick D.L., Doggett J.W., et al. Antidepressant medication use and restless legs syndrome in patients presenting with insomnia. Sleep Med 2005, 6:443-450.
34. Campbell S.S., Gillin J.C., Kripke D.F., et al. Lithium delays circadian phase of temperature and REM sleep in a bipolar depressive: a case report. Psychiatry Res 1989, 27:23-29.
35. Carskadon M., Cavallo A., Rosekind M. Sleepiness and nap sleep following a morning dose of clonidine. Sleep 1989, 12:338-344.
36. Cender D., Gelhot A., Phillips B., et al. Daytime drowsiness: is a drug to blame?. J Respir Dis 1998, 19:617-629.
37. Chalon S., Pereira A., Lainey E., et al. Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology (Berl) 2005, 177:357-365.
38. Charney D.S., Kales A., Soldatos C.R., et al. Somnambulistic-like episodes secondary to combined lithium-neuroleptic treatment. Br J Psychiatry 1979, 135:418-424.
39. Chouinard G., Beauclair L., Belanger M.C. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders [letter]. Can J Psychiatry 1998, 43:305.
40. Chrisp P., Mammen G., Sorkin E. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1991, 1:228-248.
41. Clark C., Gillin J., Golshan S., et al. Polysomnography and depressive symptoms in primary alcoholics with and without a lifetime diagnosis of secondary depression and in patients with primary major depression. J Affective Disord 1999, 52:177-185.
42. Cohn T., Foster J., Peters T. Sequential studies of sleep disturbance and quality of life in abstaining alcoholics. Addict Biol 2003, 8:455-462.
43. Cohrs S., Rodenbeck A., Guan Z., et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl) 2004, 174:421-429.
44. Cordeiro Q.J., Araujo Medrado D.E., Faria M., et al. Depression, insomnia, and memory loss in a patient with chronic intoxication by inorganic mercury. J Neuropsychiatry Clin Neurosci 2003, 15:457-458.
45. Cousens K., Dimascio A. Delta-9-THC as an hypnotic. An experimental study of 3 dose levels. Psychopharmacologia 1973, 33:355-364.
46. Cunningham L.A., Borison R.L., Carman J.S., et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994, 14:99-106.
47. Daly R., Su T., Schmidt P., et al. Cerebrospinal fluid and behavioral changes after methyltestosterone administration: preliminary findings. Arch Gen Psychiatry 2001, 58:172-177.
48. Davila D., Hurt R., Offord K., et al. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep disordered breathing in nonsmokers. Am J Respir Crit Care Med 1994, 150:469-474.
49. Debus J.R., Rush A.J., Himmel C., et al. Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry 1988, 49:422-426.
50. De Roeck J., Cluydts R., Schotte C., et al. Explorative single-blind study on the sedative and hypnotic effects of buspirone in anxiety patients. Acta Psychiatr Scand 1989, 79:129-135.
51. Drummond S., Gillin J., Smith T., et al. The sleep of abstinent pure primary alcoholic patients: natural course and relationship to relapse. Alcohol Clin Exp Res 1998, 22:1796-1802.
52. Duran J.C., Greenspan A., Diago J.I., et al. Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia. Int Psychogeriatr 2005, 1-14.
53. Dursun S.M., Patel J.K., Burke J.G., et al. Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study. J Psychiatry Neurosci 1999, 24:333-337.
54. Eastman C., Rechtschaffen A. Effect of thyroxine on sleep in the rat. Sleep 1979, 2:215-232.
55. Ehrenberg B.L., Eisensehr I., Corbett K.E., et al. Valproate for sleep consolidation in periodic limb movement disorder. J Clin Psychopharmacol 2000, 20:574-578.
56. Eisensehr I., Ehrenberg B.L., Rogge Solti S., et al. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. J Neurol 2004, 251:579-583.
57. Feinberg I., Jones R., Walker J., et al. Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clin Pharmacol Ther 1975, 17:458-466.
58. Feinberg I., Jones R., Walker J., et al. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin Pharmacol Ther 1976, 19:782-794.
59. Fernando A., Chew G. Chronic insomnia secondary to chronic pain responding to quetiapine. Australas Psychiatry 2005, 13:86.
60. Firneisz G., Szalay F., Halasz P., et al. Hypersomnia in Wilson's disease: an unusual symptom in an unusual case. Acta Neurol Scand 2000, 101:286-288.
61. Fischer R., Lang S.M., Leitl M., et al. Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude. Eur Respir J 2004, 23:47-52.
62. Fitzpatrick M.F., Mackay T., Driver H., et al. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist. BMJ 1990, 301:1365-1368.
63. Foldvary-Schaefer N., De Leon Sanchez I., Karafa M., et al. Gabapentin increases slow-wave sleep in normal adults. Epilepsia 2002, 43:1493-1497.
64. Food and Drug Administration Phenylpropanolamine-Containing Drug Products for Over-the-Counter Human Use; Tentative and Final Monographs 2005, Department of Health and Human Services. National Archives and Records Administration NARA, Washington DC.
65. Foral P.A., Malesker M.A., Hopkins H. Medication effects on sleep. Review of Sleep Medicine 2003, Butterworth Heinemann, Burlington, MA. T.J. Bowman (Ed.).
66. Freemon F. The effect of delta-9-tetrahydrocannabinol on sleep. Psychopharmacology 1974, 35:39-44.
67. Freemon F. The effect of chronically administered delta-9-tetrahydrocannabinol upon the polygraphically monitored sleep of normal volunteers. Drug Alcohol Depend 1982, 10:345-353.
68. Friess E., Tagaya H., Trachsel L., et al. Progesterone-induced changes in sleep in male subjects. Am J Physiol Endocrinol Metab 1997, 272:E885-E891.
69. 2 receptors?. Psychopharmacology (Berl) 1989, 98:139-140.
70. Frucht S., Rogers J., Greene P. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908-1910.
71. Frucht S., Greene P., Fahn S. Sleep episodes in Parkinson's disease: a wake-up call. Mov Disord 2000, 15:601-603.
72. Garcia-Borreguero D., Larrosa O., De La Llave Y., et al. Treatment of restless legs syndrome with gabapentin. A double-blind, cross-over study. Neurology 2002, 59:1573-1579.
73. Gillin J., Drummond S., Clark C., et al. Medication and substance abuse. Principles and Practice of Sleep Medicine 2005, Elsevier Saunders, Philadelphia. 4th edn. M. Kryger, T. Roth, W.C. Dement (Eds.).
74. Goldstein D.J., Lu Y., Detke M.J., et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004, 24:389-399.
75. Gossop M., Bradley B., Brewis R. Amphetamine withdrawal and sleep disturbance. Drug Alcohol Depend 1982, 10:177-183.
76. Gothe B., Strohl K., Levin S., et al. Nicotine: a different approach to treatment of obstructive sleep apnea. Chest 1985, 87:11-17.
77. Grace R. The effects of variable-dose diazepam on dreaming and emergence phenomena in 400 cases of ketamine-fentanyl anaesthesia. Anaesthesia 2003, 58:904-910.
78. Grunstein R., Sullivan C. Sleep apnea and hypothyroidism: mechanisms and management. Am J Med 1988, 85:775-779.
79. Guelfi J.D., Ansseau M., Timmerman L., et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001, 21:425-431.
80. Guilleminault C. Sleep apnea syndromes: impact of sleep and sleep states. Sleep 1980, 3:227-234.
81. Hajak G., Rodenbeck A., Voderholzer U., et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001, 62:453-463.
82. Hamner M.B., Brodrick P.S., Labbate L.A. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001, 13:141-146.
83. Hasegawa Y., Emori K., Suzuki M., et al. Restless legs syndrome successfully treated with trazodone. Sleep and Biological Rhythms 2004, 2:65-66.
84. 2 induces sleep when infused into the cerebral ventricle of conscious monkeys. Adv Prostaglandin Thromboxane Leukot Res 1987, 17B:946-948.
85. Hays J., Ockene J., Brunner R., et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003, 348:1839-1854.
86. Hein H., Behnke G., Jorres R.A., et al. The therapeutic effect of theophylline in mild obstructive sleep apnea/hypopnea syndrome: results of repeated measurements with portable recording devices at home. Eur J Med Res 2000, 5:391-399.
87. Hening W., Allen R., Walters A., et al. Motor functions and dysfunctions of sleep. Sleep Disorders Medicine: Basic Science, Technical Considerations, and Clinical Aspects 1999, Butterworth-Heinemann, Woburn. S. Chokroverty, R. Daroff (Eds.).
88. Hicks J.A., Argyropoulos S.V., Rich A.S., et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 2002, 180:528-535.
89. Hindmarch I., Dawson J., Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005, 28:187-193.
90. Hinze-Selch D., Mullington J., Orth A., et al. Effects of clozapine on sleep: a longitudinal study. Biol Psychiatry 1997, 42:260-266.
91. Hollister L.E. Marijuana (cannabis) as medicine. Journal of Cannabis Therapeutics 2001, 1:5-27.
92. Horne J., Shackell B. Slow wave sleep elevations after body heating: proximity to sleep and effects of aspirin. Sleep 1987, 10:383-392.
93. Hu K., Li Q., Yang J., et al. The effect of theophylline on sleep-disordered breathing in patients with stable chronic congestive heart failure. Chin Med J (Engl) 2003, 116:1711-1716.
94. Hutchison T., Shahan D., Anderson M. Drugdex System 2001, Micromedex, Englewood, CO.
95. Huynh N., Lavigne G., Lanfranchi P., et al. The effect of 2 sympatholytic medications - propranolol and clonidine - on sleep bruxism: experimental randomized controlled studies. Sleep 2006, 29:307-316.
96. Issa F., Sullivan C. Alcohol, snoring and sleep apnea. J Neurol Neurosurg Psychiatry 1982, 45:353-359.
97. Jacobsen F.M. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. J Clin Psychiatry 1990, 51:298-302.
98. Jansen K. Ecstasy (MDMA) dependence. Drug Alcohol Depend 1999, 53:121-124.
99. Jha A., Sharma S., Tandon N., et al. Thyroxine replacement therapy reverses sleep-disordered breathing in patients with primary hypothyroidism. Sleep Med 2006, 55-61.
100. Johanson C., Roehrs T., Schuh K., et al. The effects of cocaine on mood and sleep in cocaine-dependent males. Exp Clin Psychopharmacol 1999, 7:338-346.
101. Josephs K.A., Ahlskog J.E., Klos K.J., et al. Neurologic manifestations in welders with pallidal MRI T1 hyperintensity. Neurology 2005, 64:2033-2039.
102. Juri C., Chana P., Tapia J., et al. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin Neuropharmacol 2005, 28:185-187.
103. Kanno O., Clarenbach P. Effects of clinidine and yohimbine on sleep in man: polygraphic study and EEG analysis by normalized slope descriptors. Electroencephalogr Clin Neurophysiol 1985, 60:478-484.
104. Kaplan J., Fredrickson P.A., Renaux S.A., et al. Theophylline effect on sleep in normal subjects. Chest 1993, 103:193-195.
105. Karam-Hage M., Brower K.J. Gabapentin treatment for insomnia associated with alcohol dependence [letter]. Am J Psychiatry 2000, 157:151.
106. Karam-Hage M., Brower K.J. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci 2003, 57:542-544.
107. Kay D. Human sleep and EEG through a cycle of methadone dependence. Electroencephalogr Clin Neurophysiol 1975, 38:35-43.
108. Kay D., Einstein R., Jasinski D. Morphine effects on human REM state, waking state and NREM sleep. Psychopharmacologia 1969, 14.
109. Kaynak H., Kaynak D., Gozukirmizi E., et al. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med 2004, 5:15-20.
110. Kernan W., Viscoli C., Brass L., et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000, 343:1826-1832.
111. Ketter T.A., Malow B.A., Flamini R., et al. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 1996, 23:129-137.
112. Kilburn K.H., Mckinley K.L. Persistent neurotoxicity from a battery fire: is cadmium the culprit?. South Med J 1996, 89:693-698.
113. Kirkby H., Nielsen C.J., Nielsen V.K., et al. Subjective symptoms after long term lead exposure in secondary lead smelting workers. Br J Ind Med 1983, 40:314-317.
114. Klein E., Mairaz R., Pascal M., et al. Discontinuation of lithium treatment in remitted bipolar patients: relationship between clinical outcome and changes in sleep-wake cycles. J Nerv Ment Dis 1991, 179:499-501.
115. Kostis J., Rosen R., Holzer B., et al. CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males. Psychopharmacology 1990, 102:163-170.
116. Kowatch R., Schnoll S., Knisely J., et al. Electroencephalographic sleep and mood during cocaine withdrawal. Journal of Addictive Disorders 1992, 11:21-45.
117. Kraft M., Wenzel S.E., Bettinger C.M., et al. The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Chest 1997, 111:1249-1254.
118. Kraus T., Schuld A., Pollmacher T. Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol 1999, 19:478-479.
119. LaJambe C., Kamimori G., Belenky G., et al. Caffeine effects on recovery sleep following 27 h total sleep deprviation. Aviat Space Environ Med 2005, 76:108-113.
120. Lake C., Rosenberg D., Gallant S., et al. Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther 1990, 47:675-685.
121. Lammers G., Arends J., Declereck A., et al. Gammahydroxybutyrate and narcolepsy: a double-blind placebo controlled study. Sleep 1993, 16.
122. Landolt H.P., Raimo E.B., Schnierow B.J., et al. Sleep and sleep electroencephalogram in depressed patients treated with phenelzine. Arch Gen Psychiatry 2001, 58:268-276.
123. Landolt H., Retey J., Tonz K., et al. Caffeine attenuates waking and sleep electroencephalographic markers of sleep homeostasis in humans. Neuropsychopharmacology 2004, 29:1933-1939.
124. Landry P., Warnes H., Nielsen T., et al. Somnambulistic-like behaviour in patients attending a lithium clinic. Int Clin Psychopharmacol 1999, 14:173-175.
125. Larsen J., Tanberg E. Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drugs 2001, 15:267-275.
126. Le Bon O., Murphy J.R., Staner L., et al. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol 2003, 23:377-383.
127. Leeman A., O'Neill C., Nicholson P. Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Pharmacol 1987, 24.
128. Legros B., Bazil C.W. Effects of antiepileptic drugs on sleep architecture: a pilot study. Sleep Med 2003, 4:51-55.
129. Lemon M., Strain J., Farver D. Sodium oxybate for cataplexy. Ann Pharmacother 2006, 40:433-440.
130. Leppik I.E. Felbamate. Epilepsia 1995, 36(Suppl 2):S66-S72.
131. Lilis R., Valciukas J.A., Weber J.P., et al. Effects of low-level lead and arsenic exposure on copper smelter workers. Arch Environ Health 1985, 40:38-47.
132. Lu M.L., Shen W.W. Sleep-related eating disorder induced by risperidone. J Clin Psychiatry 2004, 65:273-274.
133. Luthringer R., Toussaint M., Schaltenbrand N., et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol Bull 1996, 32:637-646.
134. Lydic R., Baghdoyan H. Ketamine and MK-801 decrease acetylcholine release in the pontine reticular formation, slow breathing, and disrupt sleep. Sleep 2002, 25:615-620.
135. MacLean A., Cairns J. Dose response effects on ethanol on the sleep of young men. J Stud Alcohol 1982, 43:434-444.
136. Maixner S., Tandon R., Eiser A., et al. Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension. Am J Psychiatry 1998, 155:1600-1602.
137. Mamelak M., Black J., Montplaisir J., et al. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004, 27:1327-1334.
138. Man G.C., Champman K.R., Ali S.H., et al. Sleep quality and nocturnal respiratory function with once-daily theophylline (Uniphyl) and inhaled salbutamol in patients with COPD. Chest 1996, 110:648-653.
139. Manfredi R.L., Kales A., Vgontzas A.N., et al. Buspirone: sedative or stimulant effect?. Am J Psychiatry 1991, 148:1213-1217.
140. Mann K., Rossbach W., Muller M.J., et al. Heart rate variability during sleep in patients with schizophrenia treated with olanzapine. Int Clin Psychopharmacol 2004, 19:325-330.
141. Mathias S., Wetter T.C., Steiger A., et al. The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging 2001, 22:247-253.
142. Matsumoto A.M., Sandblom R.E., Schoene R.B., et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 1985, 22:713-721.
143. Mayers A.G., Baldwin D.S. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005, 20:533-559.
144. McAinsh J., Cruickshank J. Beta-blockers and central nervous system side effects. Pharmacol Ther 1990, 46:163-197.
145. McGregor C., Srisurapanont M., Jittiwutikarn J., et al. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005, 100:1320-1329.
146. Metz A., Shader R. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. Int Clin Psychopharmacol 1990, 5:191-194.
147. Midgley S.J., Heather N., Davies J.B. Dependence producing potential of anabolic-androgenic steroids. Addict Res 1999, 7:539-550.
148. Mitler M., Dawson A., Henriksen S., et al. Bedtime ethanol increases resistance of upper airways and produces sleep apneas in asymptomatic snorers. Alcohol Clin Exp Res 1988, 12:801-805.
149. Montgomery S.A. The advantages of paroxetine in different subgroups of depression. Int Clin Psychopharmacol 1992, 6(Suppl 4):91-100.
150. Montgomery I., Oswald I., Morgan K., et al. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 1983, 16:139-144.
151. Monti J.M., Monti D. Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev 2004, 8:133-148.
152. Montplaisir J., Lorrain J., Denesle R., et al. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 2001, 8:10-16.
153. Morin C., Koetter U., Bastien C., et al. Valerian-hops and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005, 28:1465-1471.
154. Mouret J., Lemoine P., Minuit M.P., et al. Effects of trazodone on the sleep of depressed subjects - a polygraphic study. Psychopharmacology 1988, 95:S37-S43.
155. Muller M.J., Rossbach W., Mann K., et al. Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms. Pharmacopsychiatry 2004, 37:157-162.
156. Mulloy E., McNicholas W.T. Theophylline in obstructive sleep apnea. A double-blind evaluation. Chest 1992, 101:753-757.
157. Mulloy E., McNicholas W.T. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1993, 148:1030-1036.
158. Murphy P., Badia P., Myers B., et al. Nonsteroidal anti-inflammatory drugs affect normal sleep patterns in humans. Physiol Behav 1994, 55:1063-1066.
159. National Institute on Drug Abuse (NIDA) Cocaine Effects 2005, National Institutes of Health, Bethesda, MD.
160. National Institute on Drug Abuse (NIDA) What is nicotine? Research Report Series - Nicotine Addiction 2005, National Institutes of Health, Bethesda, MD.
161. National Sleep Foundation Sleep in America Poll 2005, National Sleep Foundation, Washington DC.
162. Nausieda P., Glantz R., Weber S. Psychiatric complications of levodopa therapy of Parkinson's disease. Adv Neurol 1984, 40:271-277.
163. Nicholson A., Turner C., Stone B., et al. Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early morning behavior in young adults. J Clin Psychopharmacol 2004, 24:305-313.
164. Nierenberg A.A., Adler L.A., Peselow E., et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994, 151:1069-1072.
165. Nofzinger E., Van Kammen D., Gilbertson M., et al. Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-free. Biol Psychiatry 1993, 33:829-835.
166. Nofzinger E.A., Reynolds C.F.R., Thase M.E., et al. REM sleep enhancement by bupropion in depressed men. Am J Psychiatry 1995, 152:274-276.
167. Nofzinger E.A., Fasiczka A., Berman S., et al. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry 2000, 61:858-862.
168. Nofzinger E.A., Berman S., Fasiczka A., et al. Effects of bupropion SR on anterior paralimbic function during waking and REM sleep in depression: preliminary findings using. Psychiatry Res 2001, 106:95-111.
169. Nolen W.A., Haffmans P.M., Bouvy P.F., et al. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993, 28:189-197.
170. Novak M., Shapiro C. Drug induced sleep disturbances. Drug Safety 1997, 16:133-148.
171. Nowell P.D., Reynolds C.F.R., Buysse D.J., et al. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry 1999, 60:89-95.
172. Obermeyer W., Benca R. Effects of drugs on sleep. Neurol Clin 1996, 14:827-840.
173. Oga K., Kojima T., Matsuura M., et al. Effects of low-dose ketamine on neuropathic pain: an electroencephalogram-electrooculogram/behavioral study. Psychiatry Clin Neurosci 2002, 56:355-363.
174. Olanow C., Schapira A., Roth T. Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole [letter]. Neurology 2000, 54:274-277.
175. 2-receptor antagonists on subjective and objective assessment of sleep. Aliment Pharmacol Ther 1994, 8:203-207.
176. Ostroff R.B., Nelson J.C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999, 60:256-259.
177. O'Suilleabhain P., Dewey R.J. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson's disease. Arch Neurol 2002, 59:986-989.
178. Oswald I., Adam K. Effects of paroxetine on human sleep. Br J Clin Pharmacol 1986, 22:97-99.
179. Ott G.E., Rao U., Lin K.M., et al. Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response. Int J Neuropsychopharmacol 2004, 7:275-281.
180. Pace-Schott E., Stickgold R., Mazur A., et al. Sleep quality deteriorates over a binge-abstinence cycle in chronic smoked cocaine users. Psychopharmacology 2005, 179:873-883.
181. Paquet V., Strul J., Servais L., et al. Sleep-related eating disorder induced by olanzapine. J Clin Psychiatry 2002, 63:597.
182. Parrino L., Spaggiari M.C., Boselli M., et al. Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology 1994, 116:389-395.
183. Parrott A. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 2001, 16:557-577.
184. Paus S., Brecht H., Koster J., et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003, 18.
185. Paykel E., Fleminger R., Watson J. Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacology 1982, 2:14-39.
186. Perez Bravo A. [Topiramate use as treatment in restless legs syndrome.]. Actas Esp Psiquiatr 2004, 32:132-137.
187. Petrie G.R., Chookang J.Y., Hassan W.U., et al. Bambuterol: effective in nocturnal asthma. Respir Med 1993, 87:581-585.
188. Phillips B., Danner F. Cigarette smoking and sleep disturbance. Arch Intern Med 1995, 155:734-737.
189. Pivik R., Zarcone V., Dement W., et al. Delta-9-tetrahydrocannabinol and synhexyl; effects on human sleep patterns. Clin Pharmacol Ther 1972, 13:426-435.
190. Placidi F., Scalise A., Marciani M.G., et al. Effect of antiepileptic drugs on sleep. Clin Neurophysiol 2000, 111(Suppl 2):S115-S119.
191. Polo-Kantola P., Erkkola R., Helenius H., et al. When does estrogen replacement therapy improve sleep quality?. Am J Obstet Gynecol 1998, 178:1002-1009.
192. Polo-Kantola P., Erkkola R., Irjala K., et al. Effect of short-term transdermal estrogen replacement therapy on sleep: a randomized, double-blind crossover trial in postmenopausal women. Fertil Steril 1999, 71:873-880.
193. Pope H.J., Brower K. Anabolic-Androgenic Steroid Abuse 2005, Williams & Wilkins, Baltimore.
194. Prosise G., Bonnet M., Berry R., et al. Effects of abstinence from smoking on sleep and daytime sleepiness. Chest 1994, 105:1136-1141.
195. Purdie D., Empson J., Crichton C., et al. Hormone replacement therapy, sleep quality and psychological wellbeing. Br J Obstet Gynaecol 1995, 102:735-739.
196. 2, are correlated with increasing propensity towards sleep in rats. Brain Res 1997, 1997:81-89.
197. Rangaswamy M., Porjesz B., Chorlian D., et al. Resting EEG in offspring of male alcoholics: beta frequencies. Int J Psychophysiol 2004, 51:239-251.
198. Rao M.L., Clarenbach P., Vahlensieck M., et al. Gabapentin augments whole blood serotonin in healthy young men. J Neural Transm 1988, 73:129-134.
199. Rao U., Lutchmansingh P., Poland R.E. Contribution of development to buspirone effects on REM sleep: a preliminary report. Neuropsychopharmacology 2000, 22:440-446.
200. Regnell G., Widerlov E., Ekman R. Delta sleep-inducing peptide in CSF of patients with affective illness is elevated by lithium treatment. Biol Psychiatry 1988, 24:112-116.
201. 4 treatment on the prevalence and severity of obstructive sleep apnea syndrome (OSAS). J Endocrinol Invest 2005, 28:893-898.
202. Ricaurte G., McCann U. Experimental studies on 3, 4-methylenedioxymethamphetamine (MDA, " ectasy") and its potential to damage brain serotonin neurons. Neurotox Res 2001, 3:85-99.
203. Ridout F., Meadows R., Johnsen S., et al. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 2003, 18:261-269.
204. Riedel B., Durrence H., Lichstein K., et al. The relation between smoking and sleep: the influence of smoking level, health, and psychological variables. Behav Sleep Med 2004, 2:63-78.
205. Riemann D., Voderholzer U., Cohrs S., et al. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 2002, 35:165-174.
206. Riemann D.W., Feige B., Weske G., et al. Sleep in alcohol dependent patients during acute and subacute withdrawal. Sleep 2002, 25(Abstract Suppl):A267.
207. Robert S., Hamner M.B., Kose S., et al. Quetiapine improves sleep disturbances in combat veterans with PTSD: sleep data from a prospective, open-label study. J Clin Psychopharmacol 2005, 25:387-388.
208. Roehrs T., Zwyghuizen-Doorenbos A., Knox M., et al. Sedating effects of ethanol and time of drinking. Alcohol Clin Exp Res 1992, 16:553-557.
209. Roehrs T., Merlotti L., Haplin D., et al. Effects of theophylline on nocturnal sleep and daytime sleepiness/alertness. Chest 1995, 108:382-387.
210. Roehrs T., Papineau K., Rosenthal L., et al. Ethanol as a hypnotic in insomniacs: self administration and effects on sleep and mood. Neuropsychopharmacology. 1999, 20:279-286.
211. Rosenberg K.P. Gabapentin for chronic insomnia. Am J Addict 2003, 12:273-274.
212. Roth T., Wright K.P.J., Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep 2006, 29:335-341.
213. Ruigt G.S., Kemp B., Groenhout C.M., et al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990, 38:551-554.
214. Ruiz-Primo E., Jurado J., Solis H., et al. Polysomnographic effects of thyroid hormones primary myxedema. Electroencephalogr Clin Neurophysiol 1982, 53:559-564.
215. Rundell O.H., Williams H.L., Lester B.K. Sleep in alcoholic patients: longitudinal findings. Adv Exp Med Biol 1977, 85B:389-402.
216. Rush A.J., Giles D., Jarrett R., et al. Reduced REM latency predicts response to tricyclic medication in depressed outpatients. Biol Psychiatry 1989, 26:61-72.
217. Rush A., Armitage R., Gillin J., et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 1998, 44:3-14.
218. Rye D., Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 2002, 58:341-346.
219. Rye D., Bliwise D., Dihenia B., et al. Daytime sleepiness in Parkinson's disease. J Sleep Res 2000, 9:63-69.
220. Saletu B., Prause W., Anderer P., et al. Insomnia in somatoform pain disorder: sleep laboratory studies on differences to controls and acute effects of trazodone, evaluated by the Somnolyzer 24 × 7 and the Siesta database. Neuropsychobiology 2005, 51:148-163.
221. Salin-Pascual R., De La Fuente J., Galicia-Polo L., et al. Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology (Berl) 1995, 121:476-479.
222. Salin-Pascual R.J., Galicia-Polo L., Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997, 58:348-350.
223. Salin-Pascual R.J., Herrera-Estrella M., Galicia-Polo L., et al. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 1999, 46:141-143.
224. Sandblom R.E., Matsumoto A.M., Schoene R.B., et al. Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med 1983, 308:508-510.
225. Scammell T.E. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 2003, 53:154-166.
226. Scammell T.E., Matheson J. Modafinil: a novel stimulant for the treatment of narcolepsy. Expert Opin Investig Drugs 1998, 7:99-112.
227. Scharf M.B., Sachais B.A. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990, 51:13-17.
228. Scharf M., Mcdannold M., Stover R., et al. Effects of estrogen replacement therapy on rates of cyclic alternating patterns and hot-flush events during sleep in postmenopausal women: a pilot study. Clin Ther 1997, 19:304-311.
229. Schatzberg A.F., Kremer C., Rodrigues H.E., et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002, 10:541-550.
230. Schwartz J. Modafinil: new indications for wake promotion. Expert Opin Pharmacother 2005, 6:115-129.
231. Schweitzer P. Drugs that disturb sleep and wakefulness. Principles and Practice of Sleep Medicine 2005, Elsevier Saunders, Philadelphia. M. Kryger, T. Roth, W. Dement (Eds.).
232. Schweitzer P., Muehlbach M., Walsh J. Sleepiness and performance during three -day administration of certirizine or diphenhydramine. J Allergy Clin Immunol 1994, 94:716-724.
233. Sears M.R. The evolution of beta2-agonists. Respir Med 2001, 95(Suppl B):S2-S6.
234. Seidel W., Cohen S., Bliwise N., et al. Cetirizine effects on objective measures of daytime sleepiness and performance. Ann Allergy 1987, 59:58-62.
235. Sharpley A.L., Williamson D.J., Attenburrow M.E.J., et al. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology 1996, 126:50-54.
236. Sharpley A.L., Vassallo C.M., Cowen P.J. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo. Biol Psychiatry 2000, 47:468-470.
237. Sharpley A.L., Attenburrow M.E., Hafizi S., et al. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry 2005, 66:450-454.
238. Skoloda T., Alterman A., Gottheil E. Sleep Quality Reported by Drinking and Non-Drinking Alcoholics 1979, Pergamon Press, Elmsford, NY.
239. Sokolski K.N., Brown B.J. Quetiapine for insomnia associated with refractory depression exacerbated by phenelzine. Ann Pharmacother 2006, 40:567-570.
240. Soldatos C., Kales J., Scharf M., et al. Cigarette smoking associated with sleep difficulties. Science 1980, 207:551-552.
241. Sonntag A., Rothe B., Guldner J., et al. Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 1996, 4:1-13.
242. Sorelle R. FDA warns of stroke risk associated with phenylpropanolamine: cold remedies and drugs removed from store shelves. Circulation 2000, 102:e9041.
243. Staedt J., Wassmuth F., Stoppe G. Effects of chronic treatment with methadone and naltrexone on sleep in addicts. Eur Arch Psychiatry Clin Neurosci 1996, 246:305-309.
244. Staedt J., Stoppe G., Hajak G., et al. Rebound insomnia after abrupt clozapine withdrawal. Eur Arch Psychiatry Clin Neurosci 1996, 246:79-82.
245. Staner L., Kerkhofs M., Detroux D., et al. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 1995, 18:470-477.
246. Stewart I.C., Rhind G.B., Power J.T., et al. Effect of sustained release terbutaline on symptoms and sleep quality in patients with nocturnal asthma. Thorax 1987, 42:797-800.
247. Stimmel G., Dopheide J., Stahl S. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997, 17:10-21.
248. Strollo P., Atwood C., Sanders M. Medical therapy for obstructive sleep apnea-hypopnea syndrome. Principles and Practice of Sleep Medicine 2005, Elsevier, Philadelphia. M. Kryger, T. Roth, W. Dement (Eds.).
249. Taasan V., Block A., Boysen B., et al. Alcohol increases sleep apnea and oxygen desaturation in asymptomatic men. Am J Med 1981, 71:240-245.
250. Taylor S.F., Tandon R., Shipley J.E., et al. Effect of neuroleptic treatment on polysomnographic measures in schizophrenia. Biol Psychiatry 1991, 30:904-912.
251. Teichtahl H., Prodromidis A., Miller B., et al. Sleep-disordered breathing in stable methadone programme patients: a pilot study. Addiction 2001, 96:395-403.
252. Thase M.E. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999, 60(Suppl 17):28-31.
253. Thompson P., Gillin J., Golshan S., et al. Polygraphic sleep measures differentiate alcoholics and stimulant abusers during short term abstinence. Biol Psychiatry 1995, 38:831-836.
254. Thorp M.L., Morris C.D., Bagby S.P. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001, 38:104-108.
255. Touyz S.W., Beumont P.J., Saayman G.S., et al. A psychophysiological investigation of the short-term effects of clozapine upon sleep parameters of normal young adults. Biol Psychiatry 1977, 12:801-822.
256. Trenkwalder C. Parkinsonism. Principles and Practice of Sleep Medicine 2005, Elsevier Saunders, Philadelphia. 4th edn. M. Kryger, T. Roth, W. Dement (Eds.).
257. 2, a cerebral sleep inducing substance in rats. Proc Natl Acad Sci 1983, 80:1735.
258. US Department of Health and Human Services Inhalants. Substance Abuse Treatment Advisory - Breaking News for the Treatment Field 2003, vol. 3:1-8. National Institutes of Health, Bethesda, MD.
259. Valentin N., Bech B. Ketamine anaesthesia for electrocochleography in children. Are psychic side effects really rare?. Scand Audiol 1996, 25:39-43.
260. Van Bemmel A.L., Havermans R.G., Van Diest R. Effects of trazodone on EEG sleep and clinical state in major depression. Psychopharmacology 1992, 107:569-574.
261. Van Bemmel A.L., Beersma D.G., Van Den Hoofdakker R.H. Changes in EEG power density of non-REM sleep in depressed patients during treatment with trazodone. J Affect Disord 1995, 35:11-19.
262. Van Den Heuvel C., Reid K., Dawson D. Effect of atenolol on nocturnal sleep and temperature in young men: reversal by pharmacological doses of melatonin. Physiol Behav 1997, 61:795-802.
263. Van Hilten B., Hoff J., Middlekoop M. Sleep disruption in Parkinson's disease. Arch Neurol 1994, 51:922-928.
264. Vaughn B.V., D'Cruz O.F. Sleep and epilepsy. Semin Neurol 2004, 24:301-313.
265. Veale D., Cooper B.G., Griffiths C.J., et al. The effect of controlled-release salbutamol on sleep and nocturnal oxygenation in patients with asthma and chronic obstructive pulmonary disease. Respir Med 1994, 88:121-124.
266. Vir R., Bhagat R., Shah A. Sleep disturbances in clinically stable young asthmatic adults. Ann Allergy Asthma Immunol 1997, 79:251-255.
267. Vogel G., Cohen J., Mullis D., et al. Nefazodone and REM sleep: how do antidepressant drugs decrease REM sleep?. Sleep 1998, 21:70-77.
268. Walsh J.K., Zammit G., Schweitzer P.K., et al. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med 2006, 7:155-161.
269. Walter G., Lyndon B. Depression in hepatolenticular degeneration (Wilson's disease). Aust N Z J Psychiatry 1997, 31:880-882.
270. Ware J.C., Pittard J.T. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. J Clin Psychiatry 1990, 51(9 Suppl):18-22.
271. Ware J.C., Rose F.V., Mcbrayer R.H. The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep 1994, 17:544-550.
272. Weddington W., Brown B., Haertzen C., et al. Changes in mood, craving, and sleep during short term abstinence reported by male cocaine addicts. A controlled, residential study. Arch Gen Psychiatry 1990, 47:861-868.
273. Wesensten N., Killgore W., Balkin T. Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 2005, 14:255-266.
274. Wetter D.W., Young T.B. The relation between cigarette smoking and sleep disturbance. Prev Med 1994, 23:328-334.
275. Wetter D.W., Young T.B., Bidwell T., et al. Smoking as a risk factor for sleep disordered breathing. Arch Intern Med 1994, 154:2219-2224.
276. Wetter T.C., Lauer C.J., Gillich G., et al. The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs. J Psychiatr Res 1996, 30:411-419.
277. Wetter D.W., Carmack C., Anderson C., et al. Tobacco withdrawal signs and symptoms among women with and without a history of depression. Exp Clin Psychopharmacol 2000, 8:88-96.
278. Wetter T.C., Brunner J., Bronisch T. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry 2002, 35:109-111.
279. Wiegand M., Schreiber W., Lauer C., et al. The action of clenbuterol on sleep and symptomatology in depressives. Pharmacopsychiatry 1991, 24:89-92.
280. Wiegand L., Mende C.N., Zaidel G., et al. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. Chest 1999, 115:1525-1532.
281. Wiesbeck G., Schuckit M., Kalmijn J., et al. An evaluation of the history of marijuana withdrawal syndrome in a large population. Addiction 1996, 91:1469-1478.
282. Williams D., Maclean A., Cairns J. Dose-response effects of ethanol on the sleep of young women. J Stud Alcohol 1983, 44:515-523.
283. Wilson S., Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005, 65:927-947.
284. Wilson S.J., Bailey J.E., Rich A.S., et al. Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram. Eur Neuropsychopharmacol 2004, 14:367-372.
285. Wilson S., Bailey J.E., Rich A.S., et al. The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. J Psychopharmacol 2005, 19:609-613.
286. Winokur A., Sateia M.J., Hayes B., et al. Acute effects of mirtazapine on sleep continuity and sleep architacture in depressed patients: a pilot study. Biol Psychiatry 2000, 48:75-78.
287. Winokur A., Gary K.A., Rodner S., et al. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety 2001, 14:19-28.
288. Wirz-Justice A., Werth E., Savaskan E., et al. Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease. Alzheimer Dis Assoc Disord 2000, 14:212-215.
289. Wolf R., Dykierek P., Gattaz W.F., et al. Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. Pharmacopsychiatry 2001, 34:60-65.
290. Wyatt J., Cajochen C., Ritz-De Cecco A., et al. Low-dose repeated caffeine administration for circadian-phase dependent performance degredation during extended wakefulness. Sleep 2004, 27:374-381.
291. Xyrem (Sodium Oxybate) Oral Solution, P.I. Xyrem 2002, Orphan Medical, Minnetonka, MN.
292. Xyrem International Study Group Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo controlled study in 228 patients. Sleep Med 2005, 6:415-421.
293. Yamadera H., Suzuki H., Nakamura S., et al. Effects of trazodone on polysomnography, blood concentration and core body temperature in healthy volunteers. Psychiatry Clin Neurosci 1999, 53:189-191.
294. Yamashita H., Morinobu S., Yamawaki S., et al. Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol. Psychiatry Res 2002, 109:137-142.
295. Yamashita H., Mori K., Nagao M., et al. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. J Clin Psychiatry 2004, 65:1525-1530.
296. Yamashita H., Mori K., Nagao M., et al. Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults. Am J Geriatr Psychiatry 2005, 13:377-384.
297. Yang C.M., Spielman A.J., Huang Y.S. Insomnia. Curr Treat Options Neurol 2005, 7:373-386.
298. Young T.B., Peppard P., Gottlieb D. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002, 165:1217-1239.